The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg sustained release tablet to that of Wellbutrin SR sustained release tablet after a single, one-tablet dose in fasted subjects.
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design. Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men. Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
26
A: Experimental Subjects received Abrika formulated products under fasting conditions
B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
SFBC Ft. Myers, Inc.
Fort Myers, Florida, United States
Rate and Extend of Absorption
Time frame: 120 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.